Jane Street
CTMX icon

Jane Street’s CytomX Therapeutics CTMX Stock Holding History

Jane Street’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,600
Closed -$318K – 11777
2026
Q1 		$318K Buy
+67,600
New +$343K ﹤0.01% 9117
2025
Q4 		– Sell
-12,800
Closed -$40.8K – 11306
2025
Q3 		$40.8K Buy
+12,800
New +$28.8K ﹤0.01% 10399

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Jane Street's CTMX Position: Q2 2026 in Review

Jane Street sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 997,510 shares — an estimated $3.81M sold.

Jane Street first reported a position in CTMX in Q2 2020 and held it in 20 quarters. The position peaked at $4.69M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Jane Street reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 997,510 CytomX Therapeutics shares in Q2 2026, an estimated $3.81M.
  • Jane Street first reported a position in CytomX Therapeutics in Q2 2020 and held it in 20 quarters.
  • Jane Street's CytomX Therapeutics position peaked at $4.69M in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.